A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira
{"title":"他他多,一种阿片类药物作为治疗慢性疼痛的策略?叙述性回顾","authors":"A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira","doi":"10.18231/j.jpbs.2023.004","DOIUrl":null,"url":null,"abstract":"Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"144 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review\",\"authors\":\"A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira\",\"doi\":\"10.18231/j.jpbs.2023.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.\",\"PeriodicalId\":21014,\"journal\":{\"name\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"volume\":\"144 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.jpbs.2023.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research journal of pharmaceutical, biological and chemical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.jpbs.2023.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
慢性疼痛影响着大约30%的世界人口。他他多可作为对常用阿片类药物反应不充分的患者的一种镇痛选择。本研究综述了他他多疼痛治疗的一般方面及其与氧化应激增加的可能关联,以及其与抗氧化物质关联的益处。搜索在Medline (Pubmed)、Scopus、Web of Science和Google学术数据库中进行,包括自2008年该药注册以来的研究。所选的文章是关于使用他他多治疗成人和老年人慢性中重度疼痛,而非癌症相关疼痛的文章。他他多是一种微阿片受体激动剂,可抑制去甲肾上腺素的再摄取。虽然他他多的不良反应比其他传统阿片类药物少,但研究表明他他多可诱导氧化应激,但尚未阐明其机制。
Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.